THU0394 Macrophage activation syndrome in adult onset still’s disease: A single center experience
Identifieur interne : 001151 ( Main/Exploration ); précédent : 001150; suivant : 001152THU0394 Macrophage activation syndrome in adult onset still’s disease: A single center experience
Auteurs : L. O. Damian ; I. Felea ; S.-P. Simon ; M. Lupse ; C. Bodolea [Roumanie] ; L. Ghib ; R. Mocanu ; S. RednicSource :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2013-06.
English descriptors
- Teeft :
- Active traps, Adult onset disease, Adverse events, Aosd, Blood cell counts, Canakinumab, Chronic bone pain, Clinical features, Clinical manifestations, Clinical remission, Coagulation abnormalities, Complete response, Disease activity, Disease pattern, Fracture, Global assessment, Internal medicine, Macrophage activation syndrome, Novartis, Osteogenesis imperfecta, Periodic syndrome, Plasma levels, Polycyclic pattern, Primary endpoint, Remission, Rheumatology, Successful treatment, Syndrome, Treatment period.
Abstract
Background Macrophage activation syndrome (MAS) is an increasingly recognised life-threatening complication of autoimmune diseases, occurring mainly in systemic-onset juvenile idiopathic arthritis (SoJIA) and adult-onset Still’s disease (AOSD). Objectives The aim of this study is to describe the clinical features and therapy of MAS in AOSD from a single Romanian medical center. Methods The medical charts of AOSD patients seen between 2001 and 2011 in a tertiary referral center were reviewed in order to identify the cases of MAS. The adult patients with MAS and SoJIA were excluded. All patients with AOSD met the Yamaguchi criteria. MAS was diagnosed using the preliminary Ravelli criteria for SoJIA. Clinical and laboratory assessments were recorded comparatively for a patient in the episode of MAS and outside of it. Results Between the 61 patients with AOSD identified, 6 patients (4 M, 2 F, aged 24-72 years, mean age 47 yrs) had at least one flare of MAS. In 2 patients MAS was the inaugural feature of AOSD. During the MAS episode all patients hadhigh- grade continuous fever, CNS involvement and hepatomegalia. Interstitial lung involvement was seen in 4 cases. Arthritis was not prominent during the episode. Five patients had thrombocytopenia, 3 had leukopenia and all had moderate to severe anemia. Hemophagocytosis was histologically confirmed in only two cases. Ferritin values were high (460 to 22000) in all 5 cases in whom it was available; however the degree of elevation was not a reliable marker for MAS. Elevated liver enzymes and hypertriglyceridemia were constant features; hyposodemia was present only in 2 patients. Despite the coagulation abnormalities found in 4 cases, only one patient had hemorrhages. Of interest, the 4 patients with hypocomplementemia (C3 and/or C4) had a more severe form of disease and lung involvement. The therapy consisted in pulsed methylprednisolone (6 pts), mechanical ventilation (1 pt), plasmaferesis (1 pt), cyclosporine (4 pts), azathioprine (2 pts), methotrexate (1 pt), hydroxychloroquine (1 pt), colchicine (1 pt) and oral corticosteroids, according to clinical picture. After recovery from MAS, the blood cell counts and complement titers returned to normal or high values. Conclusions A high index of suspicion is necessary to identify the patients at risk for MAS in AOSD. Low blood cell counts, hypocomplementemia, hypertriglyceridemia and coagulation abnormalities could help to discriminate between a flare of AOSD and MAS, but validated guidelines are needed. Disclosure of Interest None Declared
Url:
DOI: 10.1136/annrheumdis-2012-eular.2359
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002360
- to stream Istex, to step Curation: 002360
- to stream Istex, to step Checkpoint: 000203
- to stream Main, to step Merge: 001152
- to stream Main, to step Curation: 001151
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">THU0394 Macrophage activation syndrome in adult onset still’s disease: A single center experience</title>
<author><name sortKey="Damian, L O" sort="Damian, L O" uniqKey="Damian L" first="L. O." last="Damian">L. O. Damian</name>
</author>
<author><name sortKey="Felea, I" sort="Felea, I" uniqKey="Felea I" first="I." last="Felea">I. Felea</name>
</author>
<author><name sortKey="Simon, S P" sort="Simon, S P" uniqKey="Simon S" first="S.-P." last="Simon">S.-P. Simon</name>
</author>
<author><name sortKey="Lupse, M" sort="Lupse, M" uniqKey="Lupse M" first="M." last="Lupse">M. Lupse</name>
</author>
<author><name sortKey="Bodolea, C" sort="Bodolea, C" uniqKey="Bodolea C" first="C." last="Bodolea">C. Bodolea</name>
</author>
<author><name sortKey="Ghib, L" sort="Ghib, L" uniqKey="Ghib L" first="L." last="Ghib">L. Ghib</name>
</author>
<author><name sortKey="Mocanu, R" sort="Mocanu, R" uniqKey="Mocanu R" first="R." last="Mocanu">R. Mocanu</name>
</author>
<author><name sortKey="Rednic, S" sort="Rednic, S" uniqKey="Rednic S" first="S." last="Rednic">S. Rednic</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:EB9EE9157B80CDD3FE24C590C3B04DCBE2579D11</idno>
<date when="2013" year="2013">2013</date>
<idno type="doi">10.1136/annrheumdis-2012-eular.2359</idno>
<idno type="url">https://api.istex.fr/ark:/67375/NVC-LGJ0F7NG-1/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002360</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002360</idno>
<idno type="wicri:Area/Istex/Curation">002360</idno>
<idno type="wicri:Area/Istex/Checkpoint">000203</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000203</idno>
<idno type="wicri:doubleKey">0003-4967:2013:Damian L:thu:macrophage:activation</idno>
<idno type="wicri:Area/Main/Merge">001152</idno>
<idno type="wicri:Area/Main/Curation">001151</idno>
<idno type="wicri:Area/Main/Exploration">001151</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">THU0394 Macrophage activation syndrome in adult onset still’s disease: A single center experience</title>
<author><name sortKey="Damian, L O" sort="Damian, L O" uniqKey="Damian L" first="L. O." last="Damian">L. O. Damian</name>
<affiliation></affiliation>
<affiliation><wicri:noCountry code="subField">Hospital</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Felea, I" sort="Felea, I" uniqKey="Felea I" first="I." last="Felea">I. Felea</name>
<affiliation></affiliation>
<affiliation><wicri:noCountry code="subField">Hospital</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Simon, S P" sort="Simon, S P" uniqKey="Simon S" first="S.-P." last="Simon">S.-P. Simon</name>
<affiliation></affiliation>
<affiliation><wicri:noCountry code="subField">Hospital</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Lupse, M" sort="Lupse, M" uniqKey="Lupse M" first="M." last="Lupse">M. Lupse</name>
<affiliation></affiliation>
<affiliation><wicri:noCountry code="subField">Cluj</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Bodolea, C" sort="Bodolea, C" uniqKey="Bodolea C" first="C." last="Bodolea">C. Bodolea</name>
<affiliation wicri:level="1"><country xml:lang="fr">Roumanie</country>
<wicri:regionArea>Critical Care Dept., Municipal Teaching Hospital Cluj, Cluj-Napoca</wicri:regionArea>
<wicri:noRegion>Cluj-Napoca</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Roumanie</country>
<wicri:regionArea>Critical Care Dept., Municipal Teaching Hospital Cluj, Cluj-Napoca</wicri:regionArea>
<wicri:noRegion>Cluj-Napoca</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ghib, L" sort="Ghib, L" uniqKey="Ghib L" first="L." last="Ghib">L. Ghib</name>
<affiliation></affiliation>
<affiliation><wicri:noCountry code="subField">Hospital</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Mocanu, R" sort="Mocanu, R" uniqKey="Mocanu R" first="R." last="Mocanu">R. Mocanu</name>
<affiliation></affiliation>
<affiliation><wicri:noCountry code="subField">Hospital</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Rednic, S" sort="Rednic, S" uniqKey="Rednic S" first="S." last="Rednic">S. Rednic</name>
<affiliation></affiliation>
<affiliation><wicri:noCountry code="subField">Hospital</wicri:noCountry>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of the Rheumatic Diseases</title>
<title level="j" type="abbrev">Ann Rheum Dis</title>
<idno type="ISSN">0003-4967</idno>
<idno type="eISSN">1468-2060</idno>
<imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher>
<date type="published" when="2013-06">2013-06</date>
<biblScope unit="volume">71</biblScope>
<biblScope unit="issue">Suppl 3</biblScope>
<biblScope unit="page" from="288">288</biblScope>
</imprint>
<idno type="ISSN">0003-4967</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0003-4967</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Active traps</term>
<term>Adult onset disease</term>
<term>Adverse events</term>
<term>Aosd</term>
<term>Blood cell counts</term>
<term>Canakinumab</term>
<term>Chronic bone pain</term>
<term>Clinical features</term>
<term>Clinical manifestations</term>
<term>Clinical remission</term>
<term>Coagulation abnormalities</term>
<term>Complete response</term>
<term>Disease activity</term>
<term>Disease pattern</term>
<term>Fracture</term>
<term>Global assessment</term>
<term>Internal medicine</term>
<term>Macrophage activation syndrome</term>
<term>Novartis</term>
<term>Osteogenesis imperfecta</term>
<term>Periodic syndrome</term>
<term>Plasma levels</term>
<term>Polycyclic pattern</term>
<term>Primary endpoint</term>
<term>Remission</term>
<term>Rheumatology</term>
<term>Successful treatment</term>
<term>Syndrome</term>
<term>Treatment period</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract">Background Macrophage activation syndrome (MAS) is an increasingly recognised life-threatening complication of autoimmune diseases, occurring mainly in systemic-onset juvenile idiopathic arthritis (SoJIA) and adult-onset Still’s disease (AOSD). Objectives The aim of this study is to describe the clinical features and therapy of MAS in AOSD from a single Romanian medical center. Methods The medical charts of AOSD patients seen between 2001 and 2011 in a tertiary referral center were reviewed in order to identify the cases of MAS. The adult patients with MAS and SoJIA were excluded. All patients with AOSD met the Yamaguchi criteria. MAS was diagnosed using the preliminary Ravelli criteria for SoJIA. Clinical and laboratory assessments were recorded comparatively for a patient in the episode of MAS and outside of it. Results Between the 61 patients with AOSD identified, 6 patients (4 M, 2 F, aged 24-72 years, mean age 47 yrs) had at least one flare of MAS. In 2 patients MAS was the inaugural feature of AOSD. During the MAS episode all patients hadhigh- grade continuous fever, CNS involvement and hepatomegalia. Interstitial lung involvement was seen in 4 cases. Arthritis was not prominent during the episode. Five patients had thrombocytopenia, 3 had leukopenia and all had moderate to severe anemia. Hemophagocytosis was histologically confirmed in only two cases. Ferritin values were high (460 to 22000) in all 5 cases in whom it was available; however the degree of elevation was not a reliable marker for MAS. Elevated liver enzymes and hypertriglyceridemia were constant features; hyposodemia was present only in 2 patients. Despite the coagulation abnormalities found in 4 cases, only one patient had hemorrhages. Of interest, the 4 patients with hypocomplementemia (C3 and/or C4) had a more severe form of disease and lung involvement. The therapy consisted in pulsed methylprednisolone (6 pts), mechanical ventilation (1 pt), plasmaferesis (1 pt), cyclosporine (4 pts), azathioprine (2 pts), methotrexate (1 pt), hydroxychloroquine (1 pt), colchicine (1 pt) and oral corticosteroids, according to clinical picture. After recovery from MAS, the blood cell counts and complement titers returned to normal or high values. Conclusions A high index of suspicion is necessary to identify the patients at risk for MAS in AOSD. Low blood cell counts, hypocomplementemia, hypertriglyceridemia and coagulation abnormalities could help to discriminate between a flare of AOSD and MAS, but validated guidelines are needed. Disclosure of Interest None Declared</div>
</front>
</TEI>
<affiliations><list><country><li>Roumanie</li>
</country>
</list>
<tree><noCountry><name sortKey="Damian, L O" sort="Damian, L O" uniqKey="Damian L" first="L. O." last="Damian">L. O. Damian</name>
<name sortKey="Felea, I" sort="Felea, I" uniqKey="Felea I" first="I." last="Felea">I. Felea</name>
<name sortKey="Ghib, L" sort="Ghib, L" uniqKey="Ghib L" first="L." last="Ghib">L. Ghib</name>
<name sortKey="Lupse, M" sort="Lupse, M" uniqKey="Lupse M" first="M." last="Lupse">M. Lupse</name>
<name sortKey="Mocanu, R" sort="Mocanu, R" uniqKey="Mocanu R" first="R." last="Mocanu">R. Mocanu</name>
<name sortKey="Rednic, S" sort="Rednic, S" uniqKey="Rednic S" first="S." last="Rednic">S. Rednic</name>
<name sortKey="Simon, S P" sort="Simon, S P" uniqKey="Simon S" first="S.-P." last="Simon">S.-P. Simon</name>
</noCountry>
<country name="Roumanie"><noRegion><name sortKey="Bodolea, C" sort="Bodolea, C" uniqKey="Bodolea C" first="C." last="Bodolea">C. Bodolea</name>
</noRegion>
<name sortKey="Bodolea, C" sort="Bodolea, C" uniqKey="Bodolea C" first="C." last="Bodolea">C. Bodolea</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001151 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001151 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:EB9EE9157B80CDD3FE24C590C3B04DCBE2579D11 |texte= THU0394 Macrophage activation syndrome in adult onset still’s disease: A single center experience }}
This area was generated with Dilib version V0.6.33. |